Cannabis Watch: Marijuana producer Aphria’s stock rebounds after second short seller report

This post was originally published on this site

Embattled Canadian marijuana producer Aphria Inc. saw its U.S.-listed shares rebound Thursday, after the company issued a rebuttal to a series of accusations leveled by a short seller even as new allegations were posted.

The short seller, Hindenburg Research issued another report Thursday, three days after its first batch of research that said Aphria was a “shell game with a cannabis business on the side” and called in to question the value of a number of its acquisitions. Aphria issued a lengthy statement Tuesday that defended the operations included in the Hindenburg report and Thursday morning said it has appointed a special committee to review one of the acquisitions.

By the start of trading Thursday, Aphria APHA, +22.84% APHA, +51.00%  stock had lost roughly half its value — U.S. exchanges were closed Wednesday, but the Toronto Stock Exchange, or TSX, where Aphria is also listed, remained open — but shares on the New York Stock Exchange closed up 23% Thursday.

Hindenburg’s Thursday update focused on the Aphria-backed Liberty Health Science, which trades on the Canadian Securities Exchange under the ticker LHS. Hindenburg said that its research into Liberty uncovered “multiple irregularities that raise more questions around believed undisclosed insider self-dealing. Liberty shares closed up 15% to 94 cents Thursday.

MarketWatch’s guide to pot stocks: Aphria is positioning itself as a low-cost pot producer

Many of the sector’s largest companies slid in Thursday trading. Tilray Inc. TLRY, -1.26%  fell 1.3%, GW Pharmaceuticals PLC GWPH, -3.41%  dropped 3.4%, Canopy Growth Corp. CGC, -3.53% WEED, +7.57%  fell 3.5% and Aurora Cannabis Inc. ACB, -2.22% ACB, +13.53%  dropped 2.2%. Cronos Group Inc. CRON, -2.70%  , CRON, +7.95%  which said earlier this week it was in talks with Marlboro maker Altria Group Inc. MO, +0.00%  for an investment, slid 2.7%.

Also Thursday, Canopy said it had acquired vaporizer maker Storz & Bickel GmbH & Co. KG for €145 million ($165 million) in cash. The German company has 17 filed patents and the founders of Storz are expected to remain part of the business. Canopy has at least a $4 billion war chest from the investment Constellation Brands Inc. STZ, -0.24%  made earlier this year. Acquisitions are one of the things Canopy Chief Executive Bruce Linton told MarketWatch in October he plans to accomplish with that cash.

The ETFMG Alternative Harvest ETF MJ, -1.96%  has lost 15% this year, as the S&P 500 index SPX, -0.15%  gained 0.7%. Aphria shares have dropped 62% this year.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.